. 2023 Nov 10;44(2):373–380. doi: 10.19852/j.cnki.jtcm.20231110.003

Table 2.

Reduced DRSP scores in the luteal phase in FAS and PPS (compared with cycle 0)

Group	FAS				PPS
Group	n	Cycle 1	Cycle 2	Cycle 3	n	Cycle 1	Cycle 2	Cycle 3
JXP	67	19.5±16.7	26.2±17.0	32.8±15.5	61	18.6±16.4	25.7±16.8	33.0±15.3
Placebo	69	15.0±17.8	21.7±15.7	24.4±16.1	63	13.6±17.9	20.1±15.2	23.1±15.8
P value		0.129	0.109	0.002^a		0.105	0.054	0.001^a

Notes: JXP group: JXP 6 g, twice per day on the fifth day of menstruation and continued treatment until the onset of the next menstruation for 3 menstrual cycles. Placebo group: JXP analogues 6g, twice per day on the fifth day of menstruation and continued treatment until the onset of the next menstruation for 3 menstrual cycles. DRSP: Daily Record of Severity of Problems; FAS: full analysis set; PPS: per protocol set; JXP: Jiawei Xiaoyao pill. Data were presented as mean ± standard deviation. The analysis of two-sample t test and Wilcoxon rank-sum test were used to carry out statistical test. The number in JXP and placebo group was 67 and 69 in FAS, and 61 and 63 in PPS. Compared with the placebo group, ^aP < 0.05.